150 patients very late stage RCT showing no significant difference. Treatment very late, average 16.6 days after symptom onset.
Data favorable to HCQ was deleted in the second version, see analysis [mediterranee-infection.com]
. "[HCQ] accelerate[s] the alleviation of clinical symptoms"; "More rapid alleviation of clinical symptoms with SOC plus HCQ than with SOC alone was observed during the second week since randomization"; "The efficacy of HCQ on the alleviation of symptoms, HR 8.83 [1.09-71.3], was more evident when the confounding effects of other anti-viral agents were removed"
Although the viral clearance result is not statistically significant, it is consistent with the significant 20% improved viral clearance [10‑29%]
from meta analysis of the 41 viral clearance results to date
Tang et al., 14 Apr 2020, Randomized Controlled Trial, China, peer-reviewed, 24 authors, average treatment delay 16.6 days.